Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study

Autor: Kevin L. Winthrop, Kenneth Saag, Matthew D. Cascino, Jinglan Pei, Ani John, Angelika Jahreis, Tmirah Haselkorn, Daniel E. Furst, M. Abdulky, M. Abeles, H. Adelglass, A. Ahmed, J. Alloway, J. Alper, A. Anand, J. Anderson, M. Arora, A. Askari, S. Baca, D. Bacha, S. Bagheri, S. Ballou, R. Bennett, L. Bidula, H. Blumstein, M. Bognar, A. Bohan, C. Boniske, M. Borofsky, E. Box, A. Braun, T. Brennan, L. Brent, I. Cabalar, N. Carteron, K. Chaudhary, A. Chauhan, M. Cima, A. Cochinwala, H. Cohen, K. Colburn, D. Conaway, C. Danning, K. Dao, J. Dean, I. Diab, R. Diegel, R. Ditzian‐Kadanoff, J. Dowd, C. Dugowson, A. Eggebeen, H. El‐Kadi, H. Feinberg, M. Feinman, J. Feinstein, A. Fischer, B. Foad, M. Fondal, S. Fraser, A. Fraser, P. Freeman, M. Garber, A. Goldstein, S. Golombek, N. Greenstein, M. Greenwald, C. Hakim, J. Halla, D. Hallegua, K. Han, B. Harris, H. Hauptman, J. Hirsh, M. Hoffman, J. Huntwork, M. Husni, F. Hyer, R. Hymowitz, R. Jones, S. Kanagasegar, J. Kappes, R. Keating, G. Kelly, J. Kim, C. King, D. Klashman, C. Knee, K. Kolba, G. Krick, H. Krug, U. Kumar, S. Lakhanpal, T. Lang, S. Lauter, T. Lawrence Ford, W. Lee, Y. Lee, J. Leisen, J. Levine, R. Lidman, J. Lipstate, J. Malinak, R. Marcus, D. Martin, C. Mehta, G. Melton, S. Metyas, K. Miller, R. Moidel, C. Moore, J. Mossell, G. Munoz, F. Murphy, A. Nami, J. Nascimento, N. Neal, R. Neiman, C. Neuwelt, P. Nguyen, M. Niemer, K. Oelke, M. Oza, S. Pachaidee, S. Patel, S. Pegram, M. Penmetcha, J. Perkins, A. Perl, L. Peterson, R. Pittsley, K. Portnoff, D. Rahmani, N. Raja, W. Ratnoff, M. Rezaian, C. Rhea, D. Rice, D. Ridley, A. Rivadeneira, W. Rizzo, G. Roane, P. Rocca, M. Rosen, W. Saikali, M. Saitta, A. Sankoorikal, P. Saway, P. Schneider, S. Schwartzman, C. Scoville, W. Shergy, W Shiel, R. Shurmur, D. Sikes, A. Singhal, A. Snyder, S. Songcharoen, M. Sosenko, O. Soto Raices, N. Stahl, K. Stark, M. Strachan, A. Stupi, N. Sullivan, R. Sylvester, D. Tabechian, C. Tagoe, P. Taylor, S. Thakker, M. Thakor, N. Thakur, W. Tidmore, M. Toth, D. Trostle, J. Udell, M. Van de Stouwe, R. Venuturupalli, D. Weiss, K. Weselman, D. Winn, C. Yung, E. Zable, B. Zamiri

Publikováno v: Arthritis Care & Research

Objective To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis (RA) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US (SUNSTONE [Study of the Safety of Ri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5502e0d966222c7403f4d23428329950
https://doi.org/10.1002/acr.23781

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

THU0083 The relevance of elevated crp as an inclusion criterion in clinical trials in patients with rheumatoid arthritis

Autor: E.C. Keystone, C Scoville, J Suboticki, S Zhong

Publikováno v: Poster Presentations.

Background Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) of patients (pts) with rheumatoid arthritis (RA), resulting in the potential exclusion of pts with active disease and high screen failure rates1.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f87504349031a4ac10f7021675e183e9
https://doi.org/10.1136/annrheumdis-2017-eular.2316

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.